Biotech enters 2Q14 facing its second-largest correction since the beginning of the bull run in 2009. However, buysiders believe the worst of the pullback is in the rearview mirror and expect the equity markets will remain open.

These optimists consider the pullback in March to be a modest - and healthy - correction, with sector indices off 15-18% from their peak in late February.